This Form 3 is a standard initial beneficial ownership filing with no trading activity or material news. Monitor future Form 4 filings for any open-market purchases or sales by the CEO, which could provide signals about insider conviction.
Price Chart
Executive Summary
Mathai Mammen, President & CEO of Parabilis Medicines, filed a Form 3 initial statement of beneficial ownership, disclosing stock options for approximately 5.24 million shares at exercise prices ranging from $1.48 to $3.43. This is a routine filing required upon becoming an insider and provides no new information about the company's operations or financial performance.
Key Facts
- Mathai Mammen filed Form 3 as President & CEO of Parabilis Medicines, Inc.
- Disclosed stock options to purchase approximately 5,237,155 shares of common stock.
- Options have exercise prices of $1.48, $3.14, and $3.43 per share.
- Options vest over time subject to continued service, with some performance-based vesting conditions.
- Filing includes a Limited Power of Attorney authorizing Teresa Jurgensen and Thomas Kotarakos to file future Section 16 and Schedule 13D/G forms.
Financial Impact
No financial impact; Form 3 is a routine insider ownership disclosure with no transaction or change in company fundamentals.
Risk Factors
- No material risks identified from this filing.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-264599 |
| Document: 0001193125-26-264599-index-headers.html | 0001193125-26-264599 |
| Document: 0001193125-26-264599-index.html | 0001193125-26-264599 |
| Document: 0001193125-26-264599.txt | 0001193125-26-264599 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 2d ago | Press Release | $24.79 | awaiting T+60 | — | $25.03 (+0.97%) |
Oct 19, 2026 7d ago | Press Release | $25.35 | awaiting T+60 | — | $25.03 (−1.26%) |
Sep 15, 2026 5w ago | 8-K | $36.88 | awaiting T+60 | — | $25.03 (−32.13%) |
Sep 2, 2026 7w ago | 8-K | $40.75 | awaiting T+60 | — | $25.03 (−38.58%) |
Aug 13, 2026 10w ago | 8-K | $35.67 | awaiting T+60 | — | $25.03 (−29.83%) |
Aug 13, 2026 10w ago | Press Release | $35.67 | awaiting T+60 | — | $25.03 (−29.83%) |
Jul 22, 2026 13w ago | Insider Buy | $32.81 $22.75 | ▼ −30.66% | ▼ −34.31% | $25.03 (−23.71%) |
Jun 29, 2026 17w ago | Insider Cluster | $29.19 $33.31 | ▲ +14.11% | ▲ +10.50% | $25.03 (−14.25%) |
Jun 16, 2026 18w ago | Insider Cluster | $26.03 $36.16 | ▲ +38.92% | ▲ +36.23% | $25.03 (−3.84%) |
Jun 15, 2026 18w ago | Insider Cluster | $26.59 $36.88 | ▲ +38.70% | ▲ +36.84% | $25.03 (−5.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers